



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Supplement for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/632,302
Filing Date	August 1, 2003
First Named Inventor	Li, Chester
Art Unit	1633
Examiner Name	Robert M. Kelly Quang Nguyen
Attorney Docket Number	5026CON

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
QN	1	US-5,236,838	08/17/1993	Genzyme Corporation	
	2	US- 5,686,240	11/11/1997	Mount Sinai School of Medicine	
	3	US- 5,811,406	09/22/1998	Regents of University of California	
	4	US- 5,878,680	03/09/1999	US of A, Dept of Health and Human Services	
	5	US- 5,780,014	07/14/1998	Inhale Therapeutic Systems	
QN	6	US- 6,066,626	05/23/2000	Genzyme Corporation	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
QN	7	WO 96/40964	12-19-1996	Inex Pharmaceutical Corp.		
	8	WO 97/17063	5-15-1997	Microbiological Research Authority		
	9	WO 97/19177	05-29-1997	Women's and Children's Hospital		
QN	10	WO 00/33886	06-15-2000	Genzyme Corporation		

Examiner Signature

Date Considered

4/4/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/632,302
		Filing Date	August 1, 2003
		First Named Inventor	Li, Chester
		Art Unit	1633
		Examiner Name	Robert M. Kelly <i>Quang Nguyen</i>
Sheet 2 of 2	Attorney Docket Number	5026CON	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QN	11	ARMENTANO, D. et al., "Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors", Journal of Virology, March 1997, 71(3):2408-2416	
	12	McDONALD, R.J. et al., "Safety of Airway Gene Transfer with Ad2/CFTR2:Aerosol Administration in the Nonhuman Primate", Human Gene Therapy, March 1, 1997, 8:411-422	
	13	KAPLAN, J.M. et al., "Potentiation of Gene Transfer to the Mouse Lung by Complexes of Adenovirus Vector and Polycations Improves Therapeutic Potential", Human Gene Therapy, July 1, 1998, 9:1469-1479	
	14	ZIEGLER, R.J. et al., "Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer", Human Gene Therapy, July 1, 1999, 10:1667-1682	
	15	POENARU, Livia, "Particularities of lysosomal storage diseases gene therapy", Gene Therapy, 1996, 3:1039-1041	
QN	16	BEERS, M.H. and BERKOW, R., The Merck Manual of Diagnosis and Therapy, 17 th Edition, 1999, pp. 214-215, 2338 and 2408	

Examiner Signature	<i>[Signature]</i>	Date Considered	4/4/06
--------------------	--------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.